Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201107017 Principal Investigator: Tan, Benjamin
Title: A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin with Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients with Peritoneal Carcinomatosis from Appendiceal or Colorectal Cancer
Description: The main purpose of this research is to evaluate an intraperitoneal treatment for cancer following a surgical attempt to remove as much or all of the cancer as possible. The goals of this study are to determine the safety and side effects of this treatment, and to learn the maximum tolerated dose (...MORE
___________________________________________________________________________________________________
 Number: CTSU N1048 Principal Investigator: Tan, Benjamin
Title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (N1048)
Description: This trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. ...MORE
___________________________________________________________________________________________________
 Number: ACOSOG Z6051 Principal Investigator: Mutch, Matthew
Title: A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
___________________________________________________________________________________________________
 Number: 201202001 Principal Investigator: Zuckerman, Darryl
Title: A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy
Description: The purpose of this research study is to examine whether adding treatment with TheraSphere early in the current standard for second-line chemotherapy treatment of metastatic colorectal cancer is better than the current treatment alone. Better means slowing or stopping the growth of liver tumors ...MORE
___________________________________________________________________________________________________
 Number: 201013045 Principal Investigator: Mutch, Matthew
Title: Molecular Markers to Predict the Behavior of Adenocarcinoma of the Rectum
___________________________________________________________________________________________________
 Number: 201107368 Principal Investigator: Nalbantoglu, ILKe
Title: LFAB and Colorectal Cancer
___________________________________________________________________________________________________
 Number: 201212057 Principal Investigator: Wise, Paul
Title: Cancer risks and mutation spectrum of mismatch repair gene mutations in African American families with Lynch syndrome
___________________________________________________________________________________________________
 Number: 201108327 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE
___________________________________________________________________________________________________
 Number: 201107068 Principal Investigator: Lockhart, A. Craig
Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment
Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE
___________________________________________________________________________________________________